High tumor mutation burden indicates a poor prognosis in patients with intrahepatic cholangiocarcinoma

被引:0
作者
Jian-Ping Song [1 ]
Xue-Zhi Liu [2 ]
Qian Chen [3 ]
Yan-Feng Liu [4 ]
机构
[1] Department of Organ Transplantation, Qilu Hospital, Cheeloo College of Medicine, Shandong University
[2] Department of General Surgery, Shouguang People's Hospital
[3] Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University
[4] Department of Hepatobiliary Surgery, Qilu Hospital of Shandong University
关键词
D O I
暂无
中图分类号
R735.8 [胆囊、胆道肿瘤];
学科分类号
100214 ;
摘要
BACKGROUND Intrahepatic cholangiocarcinoma(ICC) is malignancies of the biliary duct system and constitutes approximately 10%-20% of all primary liver cancers. Tumor mutation burden(TMB) is a useful biomarker across many cancer types for the identification of patients who will benefit from immunotherapy. Despite the role of TMB in calculating the effectiveness and prognosis of immune checkpoint inhibitors has been confirmed in multiple human cancer types, the prognostic value of TMB in ICC patients is rare investigated.AIM To investigate the prognostic value of TMB in patients with ICC.METHODS Data of 412 patients with ICC were included in the study. TMB was calculated as the total number of somatic non-silent protein-coding mutations divided by the coding region. The Kaplan-Meier method was used to analyze overall survival(OS), and relapse free survival(RFS). The cut-off value of TMB was determined by time-dependent receiver operating characteristic(ROC) curve. Cox regression was performed for multivariable analysis of OS. The nomogram and calibration curve were analyzed to construct and evaluate the prognostic model.RESULTS In the analysis of the time-dependent ROC curve, we defined 3.1 mut/Mb as the cut-off value of TMB. The Kaplan-Meier plot revealed that patients with high TMB had poor OS(HR = 1.47, P = 0.002) and RFS(HR = 1.42, P = 0.035). Cox regression analysis also demonstrated that TMB was an independent risk predictor for ICC(HR = 1.43, P = 0.0240). Furthermore, independent prognostic factors of ICC included CA19-9(HR = 1.78, P = 0.0005), chronic viral hepatitis(HR = 1.72, P = 0.0468), tumor resection(HR = 2.58, P < 0.0001) and disease progression(metastatic disease vs. solitary liver tumor; HR = 2.55, P = 0.0002). The nomogram and calibration curve also indicated the effectiveness of the constructed prognostic model.CONCLUSION TMB was an independent prognostic biomarker in patients with ICC. Moreover, patients with ICC with high TMB had poor OS and RFS as compared to those with low TMB.
引用
收藏
页码:790 / 801
页数:12
相关论文
共 15 条
[1]   Papillary thyroid carcinoma with a high tumor mutation burden has a poor prognosis [J].
Xie, Zhenyu ;
Li, Xin ;
Lun, Yu ;
He, Yuzhen ;
Wu, Song ;
Wang, Shiyue ;
Sun, Jianjian ;
He, Yuchen ;
Xin, Shijie ;
Zhang, Jian .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 89
[2]  
The prognostic value of TMB and the relationship between TMB and immune infiltration in head and neck squamous cell carcinoma: A gene expression-based study[J] . Lizao Zhang,Bowen Li,Yu Peng,Fan Wu,Qunxing Li,Zhaoyu Lin,Shule Xie,Liping Xiao,Xinyu Lin,Zhanpeng Ou,Tingting Cai,Haixu Rong,Song Fan,Jinsong Li.Oral Oncology . 2020
[3]  
Diagnostic and prognostic biomarkers in cholangiocarcinoma[J] . Macias Rocio I R,Kornek Miroslaw,Rodrigues Pedro M,Paiva Nuno A,Castro Rui E,Urban Sabine,Pereira Stephen P,Cadamuro Massimiliano,Rupp Christian,Loosen Sven H,Luedde Tom,Banales Jesus M.Liver international : official journal of the International Association for the Study of the Liver . 2019 (s1)
[4]  
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic[J] . Chan T A,Yarchoan M,Jaffee E,Swanton C,Quezada S A,Stenzinger A,Peters S.Annals of oncology : official journal of the European Society for Medical Oncology . 2019 (1)
[5]   Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma [J].
Nepal, Chirag ;
O'Rourke, Colm J. ;
Oliveira, Douglas V. N. P. ;
Taranta, Andrzej ;
Shema, Steven ;
Gautam, Prson ;
Calderaro, Julien ;
Barbour, Andrew ;
Raggi, Chiara ;
Wennerberg, Krister ;
Wang, Xin W. ;
Lautem, Anja ;
Roberts, Lewis R. ;
Andersen, Jesper B. .
HEPATOLOGY, 2018, 68 (03) :949-963
[6]   CEA but not CA19-9 is an independent prognostic factor in patients undergoing resection of cholangiocarcinoma [J].
Loosen, Sven H. ;
Roderburg, Christoph ;
Kauertz, Katja L. ;
Koch, Alexander ;
Vucur, Mihael ;
Schneider, Anne T. ;
Binneboesel, Marcel ;
Ulmer, Tom F. ;
Lurje, Georg ;
Schoening, Wenzel ;
Tacke, Frank ;
Trautwein, Christian ;
Longerich, Thomas ;
Dejong, Cornelis H. ;
Neumann, Ulf P. ;
Luedde, Tom .
SCIENTIFIC REPORTS, 2017, 7
[7]  
Elevated levels of circulating osteopontin are associated with a poor survival after resection of cholangiocarcinoma[J] . Sven H. Loosen,Christoph Roderburg,Katja L. Kauertz,Inês Pombeiro,Catherine Leyh,Fabian Benz,Mihael Vucur,Thomas Longerich,Alexander Koch,Till Braunschweig,Tom F. Ulmer,Christoph Heidenhain,Frank Tacke,Marcel Binneb?sel,Maximilian Schmeding,Christian Trautwein,Ulf P. Neumann,Tom Luedde.Journal of Hepatology . 2017
[8]  
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden[J] . Chalmers Zachary R,Connelly Caitlin F,Fabrizio David,Gay Laurie,Ali Siraj M,Ennis Riley,Schrock Alexa,Campbell Brittany,Shlien Adam,Chmielecki Juliann,Huang Franklin,He Yuting,Sun James,Tabori Uri,Kennedy Mark,Lieber Daniel S,Roels Steven,White Jared,Otto Geoffrey A,Ross Jeffrey S,Garraway Levi,Miller Vincent A,Stephens Phillip J,Frampton Garrett M.Genome medicine . 2017 (1)
[9]   Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma [J].
Hugo, Willy ;
Zaretsky, Jesse M. ;
Sun, Lu ;
Song, Chunying ;
Moreno, Blanca Homet ;
Hu-Lieskovan, Siwen ;
Berent-Maoz, Beata ;
Pang, Jia ;
Chmielowski, Bartosz ;
Cherry, Grace ;
Seja, Elizabeth ;
Lomeli, Shirley ;
Kong, Xiangju ;
Kelley, Mark C. ;
Sosman, Jeffrey A. ;
Johnson, Douglas B. ;
Ribas, Antoni ;
Lo, Roger S. .
CELL, 2016, 165 (01) :35-44
[10]  
Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise[J] . Saha Supriya K,Zhu Andrew X,Fuchs Charles S,Brooks Gabriel A.The oncologist . 2016 (5)